The Pallbearer E3 Ligase Promotes Actin Remodeling via RAC in Efferocytosis by Degrading the Ribosomal Protein S6

Hui Xiao, Hui Wang, Elizabeth A. Silva, James Thompson, Aurélien Guillou, John R. Yates, Jr., Nicolas Buchon, and Nathalie C. Franc

SUMMARY

Clearance of apoptotic cells (efferocytosis) is achieved through phagocytosis by professional or amateur phagocytes. It is critical for tissue homeostasis and remodeling in all animals. Failure in this process can contribute to the development of inflammatory autoimmune or neurodegenerative diseases. We found previously that the PALL-SCF E3-ubiquitin ligase complex promotes apoptotic cell clearance, but it remained unclear how it did so. Here we show that the F-box protein PALL interacts with phosphorylated ribosomal protein S6 (RpS6) to promote its ubiquitylation and proteasomal degradation. This leads to RAC2 GTPase upregulation and activation and F-actin remodeling that promotes efferocytosis. We further show that the specific role of PALL in efferocytosis is driven by its apoptotic cell-induced nuclear export. Finding a role for RpS6 in the negative regulation of efferocytosis provides the opportunity to develop new strategies to regulate this process.

INTRODUCTION

Innate immunity is the first line of host defense of all animals. It limits infection by clearing pathogens (Modlin, 2012). Humoral responses in innate immunity have been studied extensively (Shishido et al., 2012), but its cellular responses are still poorly understood. This includes phagocytosis, the process by which specialized cells, the phagocytes, recognize, engulf, and digest pathogens, tissue debris, and necrotic cells during infection and in wound healing (Brown, 1995). Phagocytosis is also critical for tissue homeostasis because approximately 50–70 billion of our cells die daily by apoptosis (Han and Ravichandran, 2011). Professional and amateur phagocytes rapidly clear these apoptotic cells (ACs), a process known as efferocytosis (Henson et al., 2001). Failure to clear ACs can promote neurodegenerative and autoimmune diseases (Fuller and Van Eldik, 2008; Muñoz et al., 2010). It has also been associated with age-related macular retinal degeneration and with systemic lupus erythematosus (Finnemann et al., 2002; Hanayama et al., 2006). A thorough understanding of phagocytosis is essential to design new drugs to fight infection and to prevent and/or treat neurodegenerative and autoimmune diseases.

Drosophila is an ideal model organism in which to study innate immune responses, including phagocytosis (Ferrandon et al., 2007). It has macrophage-like cells (Tepass et al., 1994), and Drosophila Schneider S2 cells behave like macrophages and are amenable to RNAi and biochemistry (Schneider, 1972). Using genetic and genome-wide RNAi screens, we previously identified several molecules required for efferocytosis, including Pallbearer (PALL), an F-box protein that acts within a SkpA/dCullin-1/F-box (SCF) complex (Silva et al., 2007). This PALL-SCF complex functions as an E3-ubiquitin ligase to promote efficient AC clearance (Silva et al., 2007).

E3-ubiquitin ligases are involved in a variety of biological processes where the F-box protein is generally responsible for the binding specificity of the substrate to be degraded via the proteasome (Deshaies, 1999). Many F-box proteins have specific protein-protein interaction domains, such as leucine-rich repeats, WD-40 repeats, Sec7, or others, that have facilitated the identification of their substrate(s). However, many other F-box proteins do not have such domains, making it more difficult to identify their substrates. PALL belongs to this subclass, and what its substrate(s) for degradation may be in efferocytosis is not yet known.

Here we used both biochemistry and genetics to find the PALL substrate(s). We show that PALL interacts with the ribosomal protein S6 (RpS6) and that this interaction depends on the phosphorylation of RpS6. Treatment of S2 cells with the proteasome inhibitor MG132 results in accumulation of polyubiquitylated RpS6, revealing a role for the ubiquitin-proteasome pathway in the regulation of RpS6 levels. The polyubiquitylation and degradation of RpS6 are PALL-dependent because we
observed less polyubiquitylated forms of RpS6 in pall RNAi-treated S2 cells. RNAi of RpS6 enhances AC engulfment in S2 cells, and, conversely, overexpressing RpS6 in embryonic macrophages partially inhibits AC clearance in vivo. Mutation of RpS6 suppresses the AC clearance defect phenotype of a pall mutant allele. We found that pall and RpS6 mutant macrophages have opposite F-actin phenotypes, with F-actin accumulation in pall mutants and diminished F-actin in RpS6 mutants. Also, pall and RpS6 RNAi-treated S2 cells have opposite staining phenotypes for RAC. RAC regulates actin cytoskeleton during AC clearance in Caenorhabditis elegans and mammalian systems (Gumienny et al., 2001; Kinchen et al., 2005), and RAC2 is required for efferocytosis in Drosophila S2 cells (Cuttell et al., 2008). Cells treated with pall RNAi have less total and active RAC2, whereas RpS6 RNAi-treated S2 cells have more. Importantly, overexpressing RAC2 in pall mutant macrophages rescued their phagocytosis defect. Therefore, we propose that the PALL/SCF complex promotes the proteasomal degradation of RpS6, which acts as a negative regulator of efferocytosis. This degradation leads to F-actin cytoskeleton remodeling via the upregulation and activation of RAC2, thereby promoting phagocytosis. Finally, we show that PALL is not required for phagocytosis of bacteria and that its specificity in efferocytosis is driven by its AC-induced nuclear export.

RESULTS

PALL Physically Interacts with RpS6

We proposed previously that PALL promotes efferocytosis by promoting ubiquitylation and proteasomal degradation of one or more phosphorylated substrates (Silva et al., 2007). To identify the PALL substrate(s), we established three stable S2 cell lines that express hemagglutinin (HA)-tagged, full-length PALL (HA-PALLFL), its F-box-deleted version (HA-PALLΔF), or the F-box protein SLIMB (HA-SLIMB), which plays a role in innate immunity but not in efferocytosis (Khush et al., 2002; Silva et al., 2007). We used protein extracts of these stable cell lines in immunoprecipitations (IPs) with HA antibody (Ab) and carried out comparative analyses of the IPs on SDS-PAGE. We found one endogenous protein of around 26 kDa in coimmunoprecipitations with both HA-PALLFL and HA-PALLΔF but not with HA-SLIMB. Using MALDI-TOF mass spectrometry (MS), we identified this interactor as the ribosomal protein S6 (RpS6), a component of the 40S subunit of the ribosome (Figure 1A). Although ribosomal proteins are abundant and often pulled nonspecifically in IPs, RpS6 was the only ribosomal protein being consistently pulled down with HA-PALLFL and HA-PALLΔF, but not with HA-SLIMB, in three other independent IPs subjected to comparative tandem MS (Figure 1B). RpS6 sequences recovered in the MS are indicated in blue in Figure 1C. Treatment of S2 cells with cycloheximide, an inhibitor of protein translation, did not significantly enhance or reduce the ability of S2 cells to clear ACs, arguing that the role of RpS6 in efferocytosis is independent of its role as a component of the small ribosomal subunit in the context of protein synthesis (Figure S1A available online). Deleting the F-box domain of PALL prevents its interaction with SkpA (Silva et al., 2007; Figure 1D), eliminating the possibility that RpS6 is binding to the other components of the PALL-SCF complex. We further confirmed the interaction between PALL and RpS6 in cotransfections in S2 cells using HA-PALLFL- and RpS6-FLAG-tagged constructs (Figure 1D) as well as HA-PALLFL-, HA-PALLΔF-, and RpS6-V5-tagged constructs (Figure 1E, Figure S1B). Therefore, RpS6 interacts with PALL and is a candidate substrate of PALL.

RpS6 Phosphorylation Is Required for Its Interaction with PALL

RpS6 is a component of the 40S subunit of the ribosome and the substrate of several mammalian serine/threonine protein kinases that can phosphorylate RpS6 at S233, S235, S239, S242, and S245 (S indicated in red in Figure 1C), all of which are highly conserved (Radimerski et al., 2000). One of the RpS6 peptide identified by MS included a carboxy-terminal peptide that contains the conserved serines, as highlighted in blue in Figure 1C. Substrates of F-box proteins are generally phosphorylated prior to specifically interacting with their respective F-box proteins. To address whether RpS6 phosphorylation at its conserved serines is a prerequisite for its interaction with PALL, we generated a V5-tagged mutated construct of RpS6 under the control of the metallothionin (MT)-inducible promoter where all five serines were mutated into alanines (MT-RpS6(S/A)-V5). We cotransfected this construct into S2 cells with either HA-PALLFL and HA-PALLΔF constructs, carried out IPs with HA Ab, and probed for RpS6(S/A)-V5 using V5 Ab on western blots (WBs). RpS6(S/A)-V5 could no longer coimmunoprecipitate with either HA-PALLFL or HA-PALLΔF (Figure 1E). Therefore, serine phosphorylation of RpS6 is required for its interaction with PALL.

PALL Promotes Polyubiquitylation and Proteasomal Degradation of RpS6

The interaction of phosphorylated RpS6 with PALL suggests that RpS6 is a target of the PALL-SCF complex for polyubiquitylation and proteasomal degradation. This hypothesis was further strengthened by our observation that the input level of expression of the mutated form of RpS6, RpS6(S/A)-V5, in S2 cells was greater than that of RpS6-V5 under similar cotransfection conditions as well as in the sole presence of endogenous PALL (see V5 input in Figure 1E). This result suggests that mutating the serine phosphorylation sites of RpS6 into alanines, which abolishes RpS6 interaction with PALL, prevents its ubiquitylation and degradation via the proteasome. To test this, we asked whether RpS6 could accumulate when inhibiting the proteasome. We overexpressed RpS6-V5 in HA-PALLFL-stable S2 cells in the presence or absence of the proteasome inhibitor MG132 and quantified the level of RpS6 protein in WBs. RpS6-V5 accumulated in the presence of MG132 (Figure 2A) because its expression level increased significantly by 34.2% ± 17.1% (p < 0.05) when compared with that in the absence of MG132 (Figure 2B). We could not evaluate the levels of phosphorylated RpS6 because commercial antibodies against mammalian phosphorylated RpS6 do not cross-react with Drosophila RpS6. To further address whether RpS6 is a substrate of PALL-SCF for ubiquitylation, we overexpressed RpS6-V5 with an Act5C-ubiquitin (Act5C-Ub) construct in HA-PALLFL-stable S2 cells in the presence or absence of the proteasome inhibitor MG132. We immunoprecipitated RpS6-V5 with V5 Ab and performed a
WB with ubiquitin (Ub) Ab to assess whether RpS6 could be ubiquitylated (Figure 2C). We detected several polyubiquitylated forms of RpS6 in the presence of MG132 but not in its absence (Figure 2C). These results demonstrate conclusively that RpS6 is a substrate for polyubiquitylation.

We then asked whether ubiquitylation of RpS6 was PALL-dependent. For this, we repeated the above experiments in pALL RNAi-treated S2 cells in the presence of MG132. We found that the level of detectable polyubiquitylated RpS6 was reduced by almost 55% when compared with MG132-treated control S2 cells (Figures 2D and 2E). As in Figure 2A, the level of RpS6-V5 expression was higher in MG132-treated cells than in untreated control S2 cells (see V5 input WB in Figure 2D). Together, these results demonstrate a previously unappreciated role for the ubiquitin-proteasome pathway in the regulation of RpS6 protein levels. Therefore, PALL is required for the specific interaction of RpS6 with the PALL-SCF complex and subsequent RpS6 polyubiquitylation and proteasomal degradation.

**An RpS6 Loss-of-Function Mutation Suppresses the Loss-of-Function Phenotype of pALL**

To further assess whether RpS6 acts as a substrate for polyubiquitylation and proteasomal degradation via the PALL-SCF complex in vivo, we asked whether RpS6 and pALL might interact genetically. Because a loss of function of pALL is expected to result in RpS6 accumulation, we asked whether a loss of function of RpS6 might suppress the loss-of-function phenotype of pALL, i.e., restore AC clearance in the pALL-null allele. Previously characterized pALL alleles were not single mutants of pALL but also affected neighboring genes (Silva et al., 2007). Therefore, we generated a pALLko-null allele by homologous recombination (Figures S2A–S2B′). As anticipated, pALLko macrophages have a defect in phagocytosis of ACs in vivo when compared with wild-type macrophages (Figure S2C). Of note is that pALLko does not appear to have any obvious growth-related phenotypes at any developmental stages. Although we did not look extensively for these types of phenotypes at the cellular level, the
phosphorylation of RpS6 in the context of efferocytosis is also
independent of the target of rapamycin (TOR) and S6 kinase
pathway (H.X. and N.C.F., unpublished data).

We then crossed our
\textit{pallko}
to a previously characterized
strong hypomorphic loss-of-function allele of RpS6,
\textit{RpS6WG1288} (Watson et al., 1992), and assessed the phagocytosis pheno-
types and phagocytic indices (PIs) of homozygous
\textit{pallko} macrophages that were either heterozygous or homozygous for
\textit{RpS6WG1288} by CRQ Ab and 7-amino actinomycin-D (7-AAD)
double staining and confocal microscopy (Silva et al., 2007; Figure 3).
Double-homozygous mutant macrophages were capable
develop the ACs (Figure 3 C) with a PI of 2.61 ± 0.28, similar
to that of control macrophages (Figure 3 D) and of
\textit{RpS6WG1288} homozygous macrophages (Figure 3 A) with PIs of 2.47 ± 0.16
and 2.4 ± 0.22, respectively (Figure 3 D) (p > 0.05). Therefore,
loss of function of \textit{RpS6} rescued the phagocytosis phenotype
defect of homozygous \textit{pallko} mutant macrophages, which had a PI of 1.35 ± 0.12, whereas mutating one copy of \textit{RpS6}
did not significantly affect the homozygous \textit{pallko} mutant pheno-
type (Figures 3B and 3D) (p < 0.05 compared with control, and
p > 0.05 when compared with \textit{pallko}). Together, these results
demonstrate that \textit{RpS6} and \textit{pall} interact genetically and act in
the same pathway in vivo, where \textit{RpS6} acts downstream of \textit{pall}
as its substrate for polyubiquitylation and proteasomal
degradation.

\textbf{RpS6 Acts as a Negative Regulator of Efferocytosis}

\textit{RpS6} is a substrate of \textit{PALL} for proteasomal degradation
to promote AC clearance, therefore arguing that \textit{RpS6} acts in mac-
rophages as a negative regulator of this process. In a genome-
wide RNAi screen for genes required in AC clearance in S2 cells,
we found that \textit{RpS6} RNAi treatment of S2 cells with both
\textit{DRSC18712} and \textit{DRSC25010} could enhance phagocytosis of
ACs (http://www.flyrnai.org; Figure 4).
Compared with mock-
treated S2 cells (Figure 4A), \textit{RpS6} RNAi-treated S2 cells with
\textit{DRSC25010} were more than 2-fold more phagocytic when given
a same amount of ACs (Figures 4C and 4G). RNAi-treatments of
two other components of the small ribosome subunit, such as

Figure 2. \textit{RpS6} Is a Substrate of \textit{PALL} for Polyubiquitylation and Proteasomal Degradation
\textbf{(A)} HA-PALLFL stable S2 cells transfected with \textit{RpS6-V5} and treated with or without MG132, followed by WB with V5 Ab. The tubulin WB served as a loading control.
\textbf{(B)} Graph summarizing the quantification of (A). Bars represent the relative percentage when compared with untreated (–MG132) cells ± SEM of three independent experiments.
\textbf{(C)} HA-PALLFL stable S2 cells transfected with \textit{RpS6-V5} and \textit{Act5C-Ub} constructs and treated with or without MG132. V5 Ab immunoprecipitates of \textit{RpS6} were
blotted with Ub Ab to detect polyubiquitylated forms of \textit{RpS6}. The input of \textit{RpS6-V5} protein is shown by WB of crude cell extracts with V5 Ab.
\textbf{(D)} The same experiments as in (C) but with or without pretreating the S2 cells with \textit{pall} RNAi prior to MG132 treatment and IP with V5 Ab and WB with Ub Ab. The
input of \textit{RpS6-V5} protein is shown by WB of crude cell extracts with V5 Ab.
\textbf{(E)} Graph showing the relative quantification of the mean percent ± SEM of ubiquitylated \textit{RpS6} in S2 cells without MG132 (w/MG132) and \textit{pall}-RNAi cells in the
presence of MG132 (w/MG132, pall RNAi) compared with control S2 cells with MG132 (w/MG132).
Listeria monocytogenes RpS10b (the knockdown of which enhances phagocytosis of Listeria monocytogenes [Agaïsse et al., 2005]) and RpS2, served as controls and did not significantly affect the ability of S2 cells to engulf ACs (Figures S3A and S3B).

We further tested whether RpS6 could act as an inhibitor of efferocytosis in vivo by driving the expression of two independent UAS-RpS6 transgenic lines under the control of the macrophage-specific crq-Gal4 transgene (Figures 4D–4F and 4H). Overexpressing RpS6 with either UAS-RpS6 lines resulted in a >30% decrease in phagocytosis by embryonic macrophages in vivo (compare Figures 4E and 4F with Figure 4D), with PIs of 2.36 ± 0.27 and 2.32 ± 0.31 versus 3.44 ± 0.47 in the crq-gal4 control (p < 0.05) (Figure 4H). The macrophage-specific overexpression of other components of the small ribosome subunits, including RpS2 and RpS10b, did not affect their phagocytic ability (Figure S3C). Therefore, RpS6 acts as a negative regulator of efferocytosis, which further fits with its role as a PALL substrate for polyubiquitylation and proteasomal degradation, thereby promoting efficient engulfment of ACs. Furthermore, this role for RpS6 appears to be independent of its ribosomal function.

**PALL and RpS6 Regulate F-Actin Cytoskeleton Rearrangement in Efferocytosis**

How do PALL and RpS6 act in regulating AC clearance? F-actin cytoskeleton rearrangement is an important hallmark of phagocytosis (Allen and Aderem, 1996). Recently, phosphorylated RpS6 was attributed a role in regulating F-actin organization and junctional protein recruitment at the blood-testis barrier during spermatogenesis, where increased level of phosphorylated RpS6 disrupted the barrier and colocalized with disorganized F-actin (Mok et al., 2012). Therefore, we next asked whether pall facilitates AC clearance by promoting RpS6 polyubiquitylation and degradation and subsequent F-actin remodeling. We first assessed the F-actin phenotype of mock- and pall RNAi-treated S2 cells (Figures S4A and S4B, respectively) by phalloidin staining. The F-actin immunostaining increased by 73% ± 6.4% in pall RNAi-treated S2 cells compared with the mock-treated cells (Figure S4C). The pall mRNA expression was down by about 75% in pall RNAi-treated S2 cells compared with their phagocytic ability (Figure S4D). Therefore, PALL and RpS6 regulate F-actin in vivo, we further assessed the actin phenotype of pall RNAi macrophages. As for Phalloidin staining in pall RNAi-treated S2 cells, F-actin immunostaining increased in pall RNAi macrophages (Figure 5B) compared with that of wild-type macrophages (Figure 5A). In contrast, F-actin immunostaining was weaker in RpS6 RNAi mutant macrophages (Figure 5C) compared with wild-type macrophages (Figure 5A), therefore having the anticipated opposite phenotype. Similar results were obtained with phalloidin staining of pall and RpS6 mutant macrophages in vivo (data not shown). These data argue that PALL and RpS6 play a role in regulating the F-actin cytoskeleton in Drosophila macrophages in vivo. Furthermore, pall RNAi-treated S2 cells were more rounded than mock-treated cells, with F-actin distributed evenly around their cell cortex, whereas F-actin staining was weaker in RpS6-RNAi cells and more localized at their basal membrane (i.e., at their point of contact with the glass slide) (Figures 5D and 5E). RpS6 RNAi-treated cells spread onto glass slides and made more membrane ruffles than mock-treated cells (Figures 5D and 5E). Tubulin and actin monomers expression levels in pall+ or RpS6– RNAi cells were comparable with that of mock-treated cells (Figure 6A). Therefore, PALL and RpS6 regulate F-actin cytoskeleton rearrangement in vivo and in S2 cells.

**PALL and RpS6 Regulate the Drosophila RAC2 Level and Activity in Efferocytosis**

The small GTPase RAC has been shown to play an important role in AC clearance in both C. elegans and mammalian systems (Gumienny et al., 2001; Kinchen et al., 2005) by promoting actin remodeling. In a genome-wide RNAi screen for genes required for AC clearance by S2 cells, we found a role for the small GTPase RAC2 but not for the other RAC family members,
RAC1 and MTL (Mig-2 like) (Cuttell et al., 2008). We asked whether PALL and RpS6 might regulate RAC levels and/or activity in S2 cells. On a WB of total protein extracts from RNAi-treated S2 cells, we observed that there was approximately 57% less and 40% more total RAC in pall RNAi and RpS6 RNAi cells, respectively, than in mock-treated cells (Figures 6A and 6B). We then assessed the localization of RAC and active RAC by immunostaining in these cells. Mammalian RAC1 Ab staining, which cross-reacts with Drosophila RAC1 and 2 (catalog no. 23A8, Thermo Scientific), confirmed our WB findings because RpS6- and pall RNAi-treated S2 cells exhibited increased and decreased immunostainings, respectively, compared with mock-treated S2 cells (Figure S5A). To find out whether RAC levels resulted in similar active RAC levels in the cells, we also stained these RNAi-treated cells with a monoclonal Ab directed against active mammalian RAC1. This

Figure 4. RpS6 Acts as a Negative Regulator of AC Clearance

(A–C) Phagocytosis of ACs by mock-treated (A), Rab5 RNAi-treated (B), or RpS6 RNAi-treated (C) S2 cells. Live cells are blue, and engulfed FITC-labeled ACs are green. Scale bars, 200 µm.

(D–F) Merged confocal images of yw; +; crq-Gal4, UAS-eGFP (wild-type reference) (D) and yw; UAST-RpS6; crq-Gal4, UAS-eGFP macrophages with two independent transgenic UAST-RpS6 lines, [1] and [2], in (E) and (F), respectively. ACs are stained with 7-AAD (red), and GFP-expressing macrophages appear green. Scale bars, 10 µm.

(G) Graph summarizing the quantification of (A–C) with rab5-RNAi S2 cells as a control. Bars represent the relative phagocytosis compared with mock-treated S2 cells ± SEM of three independent experiments with duplicated wells.

(H) Graph showing the mean PIs ± SEM for each genotype in (D–F).

See also Figure S5.
Ab cross-reacted with Drosophila RAC2 specifically (Figure S5B) and labeled the membranes of all treated cells. Again, pall− and RpS6 RNAi-treated S2 cells showed reduced and increased staining, respectively, compared with mock-treated S2 cells (Figure 6C). We then asked whether we could rescue the phagocytosis defect of pall by overexpressing the Drosophila UAS-Rac2 transgene in the pallhomozygous mutant under the control of the macrophage-specific crq-gal4 driver. As previously for pallhomozygous, crq-gal4;pallhomozygous macrophages had a significantly diminished PI of 1.44 ± 0.12 compared with UAS-Rac2/+; crq-gal4/+;pallhomozygous heterozygous control macrophages (PI = 2.41 ± 0.13, p < 0.001), whereas pallhomozygous rescue macrophages that overexpressed UAS-Rac2 under the control of crq-gal4 (UAS-Rac2/+;crq-gal4/+;pallhomozygous) had a PI of 2.09 ± 0.19, which was statistically significantly rescued compared with that of crq-gal4;pallhomozygous macrophages (p = 0.01) but not statistically different from the UAS-Rac2/+;crq-gal4/+;pallhomozygous heterozygous control (p = 0.3) (Figure 6D; Figures S5C–S5E). Therefore, PALL allows for the degradation of RpS6 via the proteasome that leads to the upregulation and activation of RAC2 and F-actin rearrangement to promote effecrocytosis in vivo.

Nuclear Translocation of PALL in Response to ACs Confers Its Phagocytic Specificity

Considering the role of PALL upstream of RAC2 activation in efferocytosis, and because bacteria are cleared by Drosophila hemocytes via RAC2-mediated phagocytosis (Avet-Rochex et al., 2007), we next asked whether pallhomozygous mutants were susceptible to infection. Survival rates of Gram-negative Pectobacterium carotovorum (also known as Erwinia carotovora 15 [Ec15]) and Gram-positive Enterococcus faecalis (Ef) (Figure S6A), as well as their bacterial loads (Figure S6B), were similar in pallhomozygous mutant flies and control flies. Injections of Alexa 488 (green) Escherichia coli in pallhomozygous (Figure S6C) and their control flies (Figure S6C') or of Alexa 488 Staphylococcus aureus (data not shown) or their pH-sensitive pHrodo-red equivalent (data not shown; Figures S6D and S6D') did not reveal any defect in their uptake (Figures S6C and S6C') or in their phagosomal degradation (Figures S6D and S6D'). The pallhomozygous flies survived E. coli (Figure S6E) and S. aureus (Figure S6F) septic injuries equally well as their controls, and the loss of pall did not exacerbate the phenotype of mutant flies of the IMD pathway that are susceptible to a low dose of infection by E. coli (Figure S6E). Therefore, pall is not required for bacteria killing or phagocytosis and plays a specific role in effecrocytosis.

Having found previously that ACs regulate the expression level of CRQ, which localizes at the phagosomal membranes during AC clearance and participates in effecrocytosis (Franc et al., 1996, 1999), we asked whether ACs could regulate PALL expression and/or its localization. PALL has two potential nuclear export signals (NESs) at its amino acids L6 and L10, as predicted by the NetNES 1.1 server (la Cour et al., 2004; Figure S6G). We independently expressed in S2 cells a wild-type HA-tagged PALL (HA-PALLFL; Figure S6H; Movie S1) and versions of PALL in which the leucines of its NES were mutated into alanines (HA-NESPALL; Figure S6H; Movie S2) or in which the NES was replaced by a nuclear localization signal (NLS) (HA-NLS-PALL; Figure S6H; Movie S3). After staining these cells with a HA Ab and either DAPI or DRAQ5 DNA dyes, we found that both HA-NESPALL (Figure 7B) and HA-NLS-PALL (Figure 7C) were strictly localized to the nuclei of all transfected S2 cells as anticipated. However, although HA-PALLFL was expressed in the nuclei of most transfected S2 cells, it was also found to localize both in the nuclei and cytoplasm of all transfected S2 cells that were bound to/engulfing and/or had fully ingested ACs (Figure 7A; Figure 5. PALL Promotes Actin Remodeling during AC Clearance

(A–C) Confocal micrographs of Actin (green) and CRQ (red) immunostaining of yw embryos (wild-type [WT] control in [A]), pallhomozygous (B), and RpS6WG1288 (C) mutant embryos.

(D) Confocal micrographs of mock-treated, pall RNAi, or RpS6 RNAi S2 cells stained with phallolidin, z stack images through the cells were collected 1.74 μm apart (the basal membrane is in contact with the glass slide). Scale bars, 10 μm.

(E) Schematic summarizing F-actin staining (green) distribution and cell shape for mock-treated and pall and RpS6 RNAi S2 cells seen in (D). Green lines and blue circles represent actin and nuclei, respectively. Black lines represent the slides.

See also Figure S4.
Movie S1). In contrast, mutated HA-NESPALL never translocated, even when these cells engulfed endogenous ACs (white arrow, Figure 7B; Movie S2; of note is that endogenous PALL is present in these cells), and neither did mutated HA-NLSPALL (Figure 7C; Movie S3). Moreover, HA-PALLFL remained nuclear in S2 cells that had bound or fully ingested Gram-negative (E. coli) or Gram-positive (S. aureus) bacteria (Figure 7F). Therefore, the NES is required for the translocation of PALL from the nuclei to the cytoplasm of S2 cells in response to ACs, and this translocation is dependent on the binding/recognition of ACs (Figures 7D and 7E). These results demonstrate that ACs play an active role in regulating PALL localization that promotes efferocytosis and confers PALL its specificity in this process.

**DISCUSSION**

The PALL-SCF complex and proteosomal degradation are required for efficient AC engulfment (Silva et al., 2007). However, it was not clear how this promoted efferocytosis. Here we provide insights into the molecular mechanisms by which PALL promotes efferocytosis. Upon recognition and binding of ACs, PALL translocates from the nucleus to the cytoplasm, where it forms a PALL-SCF complex and specifically interacts with and targets phosphorylated RpS6 to polyubiquitylation and degradation via the 26S proteasome, which results in an increased level and activity of RAC2, followed by actin remodeling to promote efferocytosis.

RpS6, a component of the small 40S subunit of the ribosome, has highly conserved serines that are phosphorylated by S6 and RSK kinases following a wide variety of stimuli (Meyuhas, 2008). RpS6 has long been thought to be required for various functions, including global protein synthesis, the translation of mRNAs containing a 5’ terminal oligopyrimidine tract (TOP mRNAs), cell size and proliferation, and glucose homeostasis (Meyuhas, 2008). However, RxpS6<sup>−/−</sup> knockin mice in which all five serines of RpS6 were mutated into alanines show a 2.5-fold increase rather than a decrease in global protein synthesis and have a similar rate of translational activation of TOP mRNAs (Ruvinsky et al., 2005). RpS6<sup>−/−</sup> mice have similar weights as wild-type mice, although some of their cells are small because of impaired growth as they undergo compensatory proliferation (Ruvinsky et al., 2005). RpS6<sup>−/−</sup> mice also have reduced glucose disposal capacity because of a 2-fold reduction in the secretion of circulating and pancreatic insulin by small β cells (Ruvinsky et al., 2005). In at least one study, intravenous injection of mice with rat breast carcinoma cells resulted in poorly phagocytic alveolar macrophages with reduced cell-autonomous glucose oxidation that led to tumor metastasis (Gudewicz and Saba, 1977). It will be interesting to find out whether reduced glucose oxidation in these alveolar macrophages correlates with reduced glucose homeostasis because of defective RpS6 regulation.

**Drosophila** RpS6 appears to play immune-specific roles because RpS6 mutants have overgrown lymph glands (the larval hematopoietic organs), abnormal proliferation and differentiation of enlarged hemocytes, and melanotic masses caused by erroneous encapsulation of larval tissues (Stewart and Denell, 1993; Watson et al., 1992). These phenotypes suggest that losing RpS6 results in hemocyte hyperactivation. This is consistent with our data showing that RxpS6-RNAi S2 cells are more phagocytic. We did not, however, observe any increased efferocytosis by macrophages in RpS6 mutant embryos in vivo. This is likely due to the limited amount of ACs present in the embryo compared with the excess of ACs used in our S2 cell assay. Although RpS6 acts as a negative regulator of efferocytosis, other proteins of the ribosome small subunit, including RpS2 and RpS10b, do not participate in this process because RNAi in S2 cells or in vivo overexpression experiments did not reveal any significant effect on efferocytosis (Figure S3). Yet another ribosomal protein, RpS17, appears to act as a positive regulator of efferocytosis because RNAi for RpS17 in S2 cells results in these cells being less efficient at engulfing ACs (H.X. and N.C.F., unpublished data). Further experiments will be required to determine the precise role of RpS17 in AC clearance.
However, based on these experiments, we propose that RpS6 acts in efferocytosis independently of its ribosomal function. Interestingly, mammalian RpS6 can interact with proteins outside of the ribosome, including heat shock protein 90, alpha-virus nonstructural protein, and the death-associated protein kinase (Meyuhas, 2008), and is likely to also have functions that are independent of the translational machinery.

The nuclear export of PALL in response to ACs, but not to bacteria, is particularly important because it confers a specific role for RpS6 in efferocytosis. Indeed, RpS6 RNAi in S2 cells results in an increase in phagocytosis of the Gram-positive bacterium L. monocytogenes (Agaisse et al., 2005), although the specific role of RpS6 in this system is not yet known. We carried out similar RpS6 RNAi in S2 cells with new validation amplicons that have no target effects and exposed those S2 cells to fluorescent E. coli and S. aureus bacteria. We also found that knocking down RpS6 enhanced phagocytosis of both E. coli and S. aureus (H.X. and N.C.F., unpublished data). Therefore, RpS6 acts as a negative regulator of bacterial clearance, although the mechanism by which RpS6 is regulated during this process is not known. Finally, RpS6 RNAi in S2 cells also confers tolerance to Drosophila C virus infection, although it does so by acting in the context of its ribosomal function together with other ribosomal proteins (Cherry et al., 2005). Therefore, RpS6 can play many roles in Drosophila immunity, either directly or indirectly, via its ribosomal function or more specific functions that merit further investigation.

Phosphorylated RpS6 regulates F-actin organization and junctional protein recruitment at the blood-testis barrier during spermatogenesis, where increased levels of phosphorylated RpS6 disrupt the barrier and colocalize with disorganized F-actin (Mok et al., 2012). F-actin rearrangement in phagocytosis is regulated by small GTPases of the RAC family. Our results demonstrate a negative role for Drosophila RpS6 in AC clearance and that proteasomal degradation of phosphorylated RpS6 by PALL-SCF leads to F-actin remodeling via the upregulation and activation of RAC2. RAC2 is the only GTPase required for efferocytosis in S2 cells (Cuttell et al., 2008), and overexpressing RAC2 in pallΔ mutant macrophages rescued their phagocytosis defect, therefore linking PALL and RAC2 functions in vivo. Of further note, myoblasts of RpS6−/− mice have less contractile proteins, including myosins (Ruvinsky et al., 2009), suggesting that phosphorylation of RpS6 (and perhaps its degradation) is required to regulate myosin expression. Together, these observations further argue in favor of a role for RpS6 in the regulation of specific proteins in both mouse and Drosophila rather than a role in global protein synthesis. Whether RpS6 phosphorylation and proteasomal degradation in Drosophila macrophages or in other cells result in increased levels of proteins other than RAC2 to promote efferocytosis or other RpS6-mediated functions will need further investigation.

How the degradation of phosphorylated RpS6 results in higher levels and activation of RAC2 remains to be determined. Recent studies, however, have highlighted a role for specific E3 ligases, including SCFβTr1 and HACE1, in regulating mammalian RAC1 protein levels in cell migration and tumorigenesis (Torrino et al., 2011; Zhao et al., 2013). The small GTPase RhoA is also regulated by SCFβTr1 as well as by another E3 ubiquitin ligase, Smurf1, in cell migration (Wei et al., 2013). In this instance, Synaptotagmin, an actin-associated protein, can compete with Smurf1 for binding to RhoA, thereby preventing its degradation (Asanuma et al., 2008). One possibility is that the accumulation
in the pall mutant of phosphorylated RpS6 may displace such an inhibitory protein, thereby allowing a specific E3-ubiquitin ligase to bind to and target RAC2 to polyubiquitylation and proteasomal degradation. In contrast, in a wild-type context, the PALL-SCF-mediated ubiquitylation and degradation of phosphorylated RpS6 may prevent the polyubiquitylation and degradation of RAC2 by allowing binding of a specific inhibitory protein to the RAC2-specific E3-ubiquitin ligase, resulting in elevated levels and activity of RAC2. Of note is that Smurf1 can also regulate a guanine nucleotide exchange factor (GEF) for yet another small GTPase, CDC42 (Yamaguchi et al., 2008). Therefore, the regulation of RpS6 may also lead to activation of RAC2 by indirectly regulating RAC2-specific GEFs or GAPs.

Future studies of the role of Drosophila RpS6 and the regulation of its phosphorylation and levels are likely to provide new insights into the role and regulation of mammalian RpS6 that may have implications for the development of treatments to fight autoimmune and neurodegenerative diseases. Moreover, high levels of phosphorylated RpS6 correlate with tumor progression and shorter survival prognostics in patients with esophageal squamous cell carcinoma (Chaisuparat et al., 2013). Whether RpS6 plays a role in AC clearance in mammals remains to be determined, but a lack of engulfment of cancer cells by poorly phagocytic macrophages with high levels of phosphorylated RpS6 may favor the development of this cancer. Therefore, a better understanding of the phosphorylation and regulation of RpS6 levels and its role in phagocytosis will likely provide us with drug targets to fight cancer progression.

**EXPERIMENTAL PROCEDURES**

**Fly Strains**

Most fly stocks were from the Bloomington Drosophila stock center. RpS6^{G2128S} and Stif^{Rps6}_{-556-1} flies were provided by Leonie M. Quinn (University of Melbourne) and by F. Rob Jackson (Tufts University School of Medicine), respectively. UAS transgenic fly lines were generated at BestGene or supplied by FLYORF. Fly stocks were maintained at 25°C in Superfly incubators (Genesee) on standard medium. For plasmid constructions, see Supplemental Experimental Procedures.

**Generation of HA-PALLFL, HA-PALLΔF, and HA-SLIMB Stable S2 Cell Lines**

S2 cells were transfected with Effectene (QIAGEN) according to the supplier’s protocol using 950 ng of HA-PALLFL, HA-PALLΔF, or HA-SLIMB (N terminus-tagged constructs in the pMT-N-3xHA tag vector) DNA and 50 ng of pHygro vector DNA. Cells were resuspended in complete medium with 300 μg/mL of Hygromycin B to select clones that had integrated pHygro DNA. Clones were tested for integration of pMT constructs and expression of HA-tagged proteins by WB following standard protocols after treating the cells with 0.7 mM of CuSO₄ to induce expression under the control of the MT promoter.

**Immunoprecipitations and Tandem MS Analysis**

PALL, PALLΔF, or SLIMB expression was induced with 0.7 mM CuSO₄. Cells were treated with 25 μM MG132 for 6 hr (Sigma), harvested at 48 and 72 hr post-CuSO₄ treatment, and lysed in 50 mM Tris HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, and 1% NP40 with Complete EDTA-free protease inhibitor (Roche). Lysates were centrifuged at 10,000 × g for 30 min, and supernatants were added to EZ view HA beads (Sigma) overnight at 4°C. After several washes, proteins were eluted in 0.2 M Glycine (pH 2.5) and neutralized with ammonium bicarbonate. Impurities removed by trichloro-acetic acid precipitation, and samples were subjected to tandem MS analysis (Supplemental Experimental Procedures).

**Transient Transfections and Immunoprecipitations**

S2 cells were transfected with Effectene (QIAGEN) according to the supplier’s protocol. Expression of tagged versions of RpS6, PALL, and SkpA were induced with CuSO₄ at 24 hr, and the cells were harvested and lysed at 48–72 hr after transfection. Lysates were centrifuged at 10,000 × g for 30 min, and supernatants were incubated with EZ view HA beads or anti-V5 agarose affinity gel (Sigma). Purified samples were resolved by 4%–15% gradient SDS-PAGE (Bio-Rad). In WBs, Abs were used at the following dilutions: rat anti-MA (Roche) and mouse anti-FLAG (Sigma), 1:2,000; mouse anti-V5 (Invitrogen), 1:5,000. Anti-rat or anti-mouse horseradish peroxidase (HRP)-coupled secondary Abs (Jackson ImmunoResearch Laboratories) were used at a 1:10,000 dilution, followed by ECL detection following the supplier’s protocol (Pierce).

**Stability and Ubiquitylation Assays**

For the stability assay, pAc5.1/V5-HisA-RpS6 was transiently transfected into the HA-PALLFL stable S2 cell line with Effectene (QIAGEN) according to the supplier’s instructions. The cells were then treated with CuSO₄ at 24 hr post-transfection, followed by MG132 (Sigma) at a concentration of 50 μM for 4 hr. For the ubiquitylation assay, pAc5.1/V5-HisA-RpS6 and pAc5.1/UB were transiently transfected into the HA-PALLFL stable S2 cell line with Effectene (QIAGEN). PALL expression was induced with CuSO₄ at 24 hr posttransfection. The cells were then treated with MG132 (Sigma) at a concentration of 50 μM for 4 hr, lysed, and subjected to IPs and WBs as described above. The Ub (P4D1) mouse monoclonal Ab (Santa Cruz Biotechnology) was used at a 1:2,000 dilution.

**Statistical Analyses**

Statistical p values were derived using ANOVA (for PIs) or Student’s t test and are indicated in the text and figures.

**Ends-Out Gene Targeting**

Donor targeting constructs were built by insertion of two 3 kb regions (upstream and downstream of the target gene) into two multiple cloning sites of the targeting vector pXH87. These constructs were then injected into w^{1118} embryos using established methods to obtain transgenics (Bestgene).

The ends-out gene targeting procedure was performed as described in Chen et al. (2009). To induce double-stranded DNA breaks, heat shock was performed at 38°C for 90 min on day 3 after egg-laying. Target gene-specific PCR amplification was performed using primers corresponding to a sequence within the pal gene to verify homzygous knockouts (no PCR product). cre primer sets were used as a control (Supplemental Experimental Procedures). Actin staining and RAC immunostaining were performed according to standard protocols (Supplemental Experimental Procedures).

**RAC Quantification**

RAC WBs were performed after 3 days of RNAi treatment of S2 cells as described above. Cells were lysed in 50 mM Tris HCl (pH 7.4), 0.1% SDS, 200 mM NaCl, 5 mM MgCl₂, 1 mM dithiothreitol, 1% NP40, and 10% Glycerol with Complete EDTA-free protease inhibitor (Roche) and subjected to WBs. Mouse RAC1 monoclonal Ab (catalog no. 23A8, Thermo Scientific), mouse Actin Ab (catalog no. A-2066, Sigma), and rabbit α-tubulin Ab (catalog no. 11H10, Cell Signaling Technology) were used at 1:1,000. Secondary anti-mouse and anti-rabbit HRP-coupled Abs (Jackson ImmunoResearch Laboratories) were used at 1:10,000, followed by ECL detection.

All experiments with vertebrate animals were performed at the Pocono Rabbit Farm and Laboratory in accordance with relevant institutional and national guidelines and regulations. An animal protocol (10-0013-2) was approved by the Institutional Animal Care and Use Committee of The Scripps Research Institute.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes Supplemental Experimental Procedures, six figures, and three movies and can be found with this article online at dx.doi.org/10.1016/j.devcel.2014.11.015.
AUTHOR CONTRIBUTIONS

H.X., H.W., E.S., J.T., A.G., N.B., and N.C.F. conceived, designed, and performed the experiments, analyzed and interpreted the data, and wrote the manuscript.

ACKNOWLEDGMENTS

We thank Dr. Xun Huang (Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, China) for the pXH87 plasmid; Dr. Jin Jiang (UT Southwestern Medical Center, Dallas, TX) for the pUAST-UB construct; and Dr. Leonie M. Quinn (University of Melbourne, Parkville, Australia), Dr. F. Rob Jackson (Tufts University School of Medicine, Boston, MA), and the Bloomington Stock Center and FLYORF for fly strains. We also thank Claude Desplan, Sergio Grinstein, and Céline DerMardirossian for critically reading this manuscript and Céline DerFardirossian for valuable advice on RAG and actin stainings. The work was funded by a program leader-track grant from the Medical Research Council (to N.C.F.), by core support to the MRC Cell Biology Unit (to N.C.F. and E.A.S.), by an Irvington Institute postdoctoral fellowship of the Cancer Research Institute (to H.X.), by a TSI-Advanced Discovery Institute grant provided by Novartis and NIH, National Institute of Allergy and Infectious Diseases Grant R01 AI03687-01A1 (to N.C.F.), and by Research Resource Grant P41 RR011823 of the NIH (to J.R.Y.). Stocks provided by Research Resource Grant P41 RR011823 of the NIH (to J.R.Y.). Stocks from the Bloomington Drosophila Stock Center (NIH P40OD018537) were used in this study.

Received: July 12, 2014
Revised: October 6, 2014
Accepted: November 10, 2014
Published: December 18, 2014

REFERENCES


